Arbutus Moderna RNAi LNP IP Patent COVID-19

Is Moderna’s LNP Technology a Patent Infringement against Arbutus

According to Mark Murry (CEO of Arbutus), “We have seen no evidence of a Moderna delivery system that is free of our intellectual property. Not in their publications, their presentations, or in the examples in their patent filings.”

Read more about this in a Forbes article: Moderna Can’t Escape My Intellectual Property, Says Arbutus CEO

Three credible articles discuss in detail the nature of Moderna’s (MRNA) potential violation of patents held by Arbutus (ABUS) regarding its LNP (Lipid NanoParticle) technology—the delivery mechanism of the much-anticipated mRNA1273 vaccine candidate.

Is Moderna’s COVID-19 Vaccine Using Arbutus Biopharma’s Patents?

Strong Presumption Moderna Covid Vaccine Infringes on Arbutus IP

ABUS – More Nuggets of the Covid Gem:

Other pages that discuss patent infringement or the technologies behind RNAi vaccines:

Pfizer’s covid vaccine found 90% effective but raises IP questions

MRNA-LNP COVID-19 VACCINES

mRNA vaccines: intellectual property landscape

mRNA-1273

Nanotechnology’s role in the race to find a Covid-19 vaccine

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

Curevac muddies the Moderna/Arbutus waters further

Moderna’s Mysterious Coronavirus Vaccine Delivery System

Current issues of RNAi therapeutics delivery and development

Covid-19 vaccine battle just got interesting

ABUS ARTUBUS
Moderna
pfizer covid 19 vaccine biontech
Biontech LNP tech
curevac lnp patent infringement
Arturus

Leave a Comment

Your email address will not be published.